A method for constructing a library of free DNA in body fluids and its application
Directly attacking body fluid samples by enzymes for DNA fragmentation and joining addition, solving the problems of information loss and high cost during the blood free DNA database construction process, and achieving efficient and accurate body fluid free DNA database construction and tissue traceability, suitable for prenatal treatment. Diagnosis and early detection of cancer.
Patent Information
- Application Number
- CN201780097208.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2017-11-27
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2037-11-27
AI Technical Summary
In the non-invasive prenatal diagnosis and early cancer detection, the content of free DNA in blood is low and easily lost during the database construction process, resulting in low detection sensitivity and high sequencing costs, and the inability to effectively retain information about nucleosomal DNA.
The enzyme is used to directly attack the body fluid sample, perform DNA fragmentation and add linkers to achieve micro-storey library construction of free DNA in the body fluid, and retain information about nucleosomal DNA to the maximum extent. The steps are simple and the cost is low.
It realizes efficient library construction and micro library construction of free DNA in body fluids, reduces information loss during sequencing, can accurately screen out nucleosome fragments, improves tissue traceability efficiency and detection accuracy, and is suitable for prenatal diagnosis and early cancer stages. Discover.
Smart Images

Figure GPA0000289205320000101 
Figure GPA0000289205320000111 
Figure GPA0000289205320000112
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of sequencing, and in particular to a method for constructing a library of free DNA in body fluids and the use of the library in prenatal diagnosis and early detection of cancer. Background Art
[0002] In 1948, French scientists Mandel and Matters first detected DNA fragments free from cells in human peripheral blood. These DNAs mainly originated from fragmented chromatin after apoptotic or necrotic cells were cut.
[0003] In 1997, the research team of Dennis Lo from the Chinese University of Hong Kong found that there is free DNA of the fetus in the peripheral blood of pregnant mothers, thus opening the door to genetic testing of peripheral blood of pregnant women. Genetic testing technology of peripheral blood of pregnant women is called non-invasive prenatal diagnosis technology. Its principle is: there is DNA of the fetus in the peripheral blood of pregnant mothers, and the free DNA of the blood of pregnant mothers can be sequenced and the DNA of the fetus can be separated by comparing the single nucleotide polymorphism difference with the mother's DNA, so as to perform prenatal diagnosis (Lo et al, Am. J. Hum. Genet 64, 218-224 (1999)). At present, this technology is relatively mature both at home and abroad, and mainly screens the three common chromosomal diseases, namely T21 chromosomal abnormality (Down syndrome), T18 chromosomal abnormality (Edwards syndrome) and T13 chromosomal abnormality (Patau syndrome), with a detection accuracy of more than 99%.
[0004] In addition, Lyon et al. determined that there is a certain correlation between the level of free DNA in the blood of cancer patients and the degree of metastasis of malignant tumors, providing a theoretical basis for non-invasive diagnosis of cancer. This has led to the development of early cancer detection technology: in the pathological state of cancer, due to the increase in the number of apoptotic and necrotic cells, the amount of free DNA released into the blood increases significantly; these DNAs themselves carry mutations unique to cancer cells, so the type of cancer and the progression of its development can be determined by checking the concentration or mutation state of free DNA in the blood (Morelli et al., Ann Oncol 26, 731-736 (2015)). In addition, mutations of genes such as K-ras and EGFR have been detected in the free DNA in the blood of cancer patients. These findings can be applied to the early diagnosis of malignant tumors such as lung cancer and breast cancer.
[0005] It should be noted that the human body contains more than 400 cell types. Although each cell has the same set of genomes, their gene expression levels are significantly cell-specific. This is regulated by the cell-specific epigenome. Epigenomic information includes DNA methylation, histone modification, nucleosome positioning, etc. Through this information and with the help of the cell reference epigenome database, the origin of the cell can be directly determined. The latest research shows that epigenetic information is implicit in blood free DNA, including methylation and nucleosome positioning, so it can be used for tissue tracing.
[0006] Among them, the methylation of blood free DNA can reflect the methylation level of the source tissue cells to a certain extent, and the methylation degree and location of different types of tissue cells are different, so it can be used to determine which cell type the free DNA comes from. For example, Lo et al. reported a blood free DNA methylation detection technology: blood free DNA carries the methylation status of its source cells, so it can be treated with bisulfite and then sequenced. Through the methylation analysis of blood free DNA, it can be mapped to a specific cell type, thereby realizing tissue tracing (Lo et al., PNAS 112: 5503-5512 (2015)). This study can be used in a variety of diagnoses, including prenatal diagnosis, cancer localization and diagnosis of tumor cell metastasis, and diagnosis of immune system rejection in organ transplant patients. However, this method has the following disadvantages: (1) There are fewer methylation sites on the genome, and the concentration of blood free DNA itself is low, so the detection results are often not very accurate; (2) The methylation sequencing steps are cumbersome, which may cause a large amount of DNA methylation information to be lost, resulting in low sequencing quality and severe noise.
[0007] In addition, the nucleosome positioning information in cells can be used to distinguish cell and tissue types. A large number of literature reports that the length of blood free DNA is mostly concentrated around 167bp, which is consistent with the length of a nucleosome DNA, indicating that a large amount of blood free DNA is DNA wrapped by nucleosomes. In 2016, Jay Shendure et al. extracted free DNA from the blood, constructed a sequencing library, and used a deep sequencing strategy to locate the nucleosome information of blood free DNA in different types of cells, thereby achieving tissue tracing (Shendure et al., CELL 164, 57-68 (2016); Speicher et al., Nature Genetics 48, 1273-1278 (2016)). However, this method directly extracts free DNA from the blood to build a library, and then uses the sequencing data of blood free DNA to analyze nucleosome positioning. The naked DNA present in the blood will produce noise, interfering with the positioning of normal nucleosome DNA, ultimately leading to low efficiency of tissue tracing. In addition, this method adopts a deep sequencing strategy, which makes the sequencing cost too high, making it difficult to form widespread commercial applications.
[0008] In addition, there are studies reporting on chromatin open sequencing technology specifically targeting chromatin open regions: by lysing cells and treating them with Tn5 transposase, sequencing adapters are inserted into the open regions of chromatin, and then all open chromatin regions are amplified by PCR, and libraries are constructed and sequenced (Chang et al., Curr. Protoc. Mol. Biol. 109: 21.29.1-21.29.9). However, this technology excludes the information of nucleosomal DNA, and therefore cannot be used for tissue tracing based on nucleosomal DNA.
[0009] In summary, the current conventional non-invasive prenatal diagnosis and early cancer detection are completed by first extracting blood free DNA and then performing conventional library construction. This has the following problems: (1) The content of blood free DNA is very low, and it is very easy to cause loss during the library construction process, resulting in library construction failure or low detection sensitivity; (2) The existing library construction methods are to directly extract free DNA from the blood and then sequence the extracted DNA for library construction. In the end, only the sequence or methylation information of blood free DNA can be obtained, while the nucleosome distribution information may be lost during the library construction process. (3) The sequencing cost is too high. Therefore, it is urgent to develop an efficient and sensitive blood free DNA library construction method, and this method can be used to screen the nucleosome fragments of blood free DNA for tissue tracing. Summary of the invention
[0010] In view of the defects in the above-mentioned prior art, the present invention aims to provide a method for constructing a library of free DNA in body fluids, and its use in prenatal diagnosis and early detection of cancer. The present invention uses enzymes to directly attack body fluids to fragment the free DNA therein and add adapters, without extracting free DNA from body fluids. The steps are simple and the library construction cost is low. It can not only realize the micro-library construction strategy of free DNA in body fluids, but also retain the fragment information of free nucleosomal DNA in body fluids to the maximum extent during the library construction process.
[0011] The present invention achieves the above-mentioned object through the following technical solutions.
[0012] In one aspect, the present invention provides a method for constructing a library of free DNA in a body fluid sample, comprising:
[0013] (1) Using enzymes to directly act on body fluid samples to fragment free DNA in the body fluid samples;
[0014] (2) Amplifying the fragmented DNA obtained in step 1) to obtain a body fluid free DNA library.
[0015] In a preferred embodiment, the body fluid is selected from at least one of blood, urine, and saliva. In the body fluid sample, there are two types of free DNA: one is nucleosomal DNA bound to histones, and the other is unbound naked DNA. After the enzyme action, naked DNA will be cut into fragments of about 50 bp, while nucleosomal DNA may be cut into larger fragments due to its binding to histones.
[0016] In a preferred embodiment, the enzyme is a transposase or an endonuclease; preferably, the transposase is Tn5 transposase, and the endonuclease is MNase or DNase.
[0017] Please note that both transposase and endonuclease can act directly on body fluid samples. The difference is that the implementation scheme using transposase to directly attack body fluids can directly complete both DNA fragmentation and adding adapters, while the implementation scheme using endonucleases can only complete fragmentation, and the step of adding adapters needs to be performed separately later.
[0018] In a preferred embodiment, step (1) comprises: using a transposase to perform a transposition reaction on a body fluid sample containing free DNA, so as to fragment the free DNA and add a linker sequence to obtain DNA fragments containing the linker sequence;
[0019] Preferably, step (1) further comprises: after the free DNA is fragmented and a linker sequence is added, a step of extracting nucleic acid is performed.
[0020] In a further preferred embodiment, the adapter used in the transposition reaction is an adapter mixture, which is prepared by the following steps:
[0021] 1) Annealing primer A: 5′-CTGTCTCTTATACACATCT-3′ (SEQ ID NO: 1) and primer B: 5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3′ (SEQ ID NO: 2) to obtain annealing product 1;
[0022] 2) annealing primer A: 5′-CTGTCTCTTATACACATCT-3′ (SEQ ID NO: 1) and primer C: 5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-3′ (SEQ ID NO: 3) to obtain annealing product 2;
[0023] 3) Mix the annealed product 1 and the annealed product 2 to obtain a joint mixture.
[0024] Preferably, the linker mixture is embedded with the transposase to obtain a transposase-embedded complex for use in a transposition reaction.
[0025] Further preferably, the linker mixture is encapsulated with Tagment Enzyme Advanced V5S containing transposase; preferably, the volume ratio of the linker mixture to the Tagment Enzyme Advanced V5S is 1:20-1:25, preferably 1:24.5; preferably, the encapsulation is carried out at 22-28°C, preferably at 25°C, for 40-80min, preferably 60min.
[0026] In a specific embodiment, preferably, the transposase-embedded complex is incubated with the body fluid sample under transposition reaction conditions to achieve a transposition reaction.
[0027] For the transposition reaction, preferably, the volume ratio of the transposase-embedded complex to the body fluid sample is 1:50-1:80, preferably 1:62.5;
[0028] Preferably, the transposition reaction temperature is 35-40°C, preferably 37°C;
[0029] Preferably, the transposition reaction time is 55-65 min, preferably 60 min.
[0030] In a specific example of the present invention using a transposition reaction, the Tn5 transposase used has the characteristic of randomly cutting DNA, and the free DNA exposed in the plasma (free DNA not wrapped around histones) will be cut into small fragments of about 50 bp by the Tn5 transposase, while the nucleosomal DNA (free DNA wrapped around histones) will remain longer than 50 bp. Through PE50+10 sequencing, etc., DNA fragments with different length characteristics can be distinguished, thereby screening out nucleosomal DNA sequences, analyzing and obtaining the epigenetic information of the DNA sequence and the enrichment degree in regulatory regions such as different gene promoters or enhancers and transcription initiation regions. Subsequently, the nucleosomal DNA sequences obtained by building a library can be used to realize tissue tracing of blood free DNA through these epigenetic information.
[0031] In another preferred embodiment of the present invention, step (1) comprises: treating a body fluid sample containing free DNA with an endonuclease to fragment the free DNA, and then adding adapter sequences to both ends of the obtained fragmented DNA to obtain DNA fragments containing the adapter sequences;
[0032] Preferably, step (1) further comprises: after the free DNA is fragmented, a step of extracting nucleic acid is performed.
[0033] In a preferred embodiment, the amplification in step (2) comprises two amplifications;
[0034] Preferably, after the first amplification, the number of cycles N that need to be added is determined by qPCR as the number of cycles for the second amplification.
[0035] In a preferred embodiment, the method further comprises step (3): circularizing and enzymatically digesting the body fluid free DNA library obtained in step 2);
[0036] Preferably, the cyclization comprises denaturing the double-stranded DNA in the body fluid free DNA library into single-stranded DNA, and then connecting it through an oligonucleotide fragment complementary to a partial region of the single-stranded DNA through base complementary pairing; further preferably, a mediating fragment: 5′-GCCATGTCGTTCTGTGAGCCAAGG-3′ (SEQ ID NO: 4) is used to complementarily pair with the single-stranded DNA to achieve cyclization;
[0037] Preferably, the digestion is performed using exonuclease I and exonuclease III to remove uncircularized DNA;
[0038] Preferably, step (3) further comprises: a step of purifying the enzyme cleavage product; preferably, the purification is performed using magnetic beads.
[0039] In a second aspect, the present invention further provides a method for obtaining individual epigenetic information, comprising:
[0040] (1) obtaining a body fluid free DNA library of an individual according to the method described in the first aspect;
[0041] (2) Sequencing and analyzing the body fluid free DNA library obtained in step (1) to obtain individual epigenetic information.
[0042] In a third aspect, the present invention also provides the use of the method for constructing a library of free DNA in a body fluid sample as described in the first aspect or the method for obtaining individual epigenetic information as described in the second aspect in prenatal diagnosis and early detection of cancer.
[0043] In a fourth aspect, the present invention also provides a method for prenatal diagnosis or early detection of cancer, which is achieved by the method for constructing a library of free DNA in body fluid samples as described in the first aspect or the method for obtaining individual epigenetic information as described in the second aspect.
[0044] In a fifth aspect, the present invention also provides a kit for analyzing free DNA in body fluids for prenatal diagnosis or early detection of cancer, which comprises the reagents, primers, mediating fragments or a combination of one or more thereof used in the method described in the first aspect.
[0045] Preferably, the kit comprises one or more of the following combinations:
[0046] Transposase Tn5 or MNase or Dnase enzyme;
[0047] Primer A: 5′-CTGTCTCTTATACACATCT-3′ (SEQ ID NO: 1), Primer B: 5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3′ (SEQ ID NO: 2) and Primer C: 5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-3′ (SEQ ID NO: 3):
[0048] Mediator fragment: 5′-GCCATGTCGTTCTGTGAGCCAAGG-3′ (SEQ ID NO: 4); and
[0049] The enzymes and / or reagents required for the transposition, PCR amplification, enzyme digestion and ligation reactions.
[0050] Advantages of the present invention over the prior art
[0051] As mentioned above, in the prior art, a method is usually adopted in which free DNA is first extracted from a body fluid sample, and then the DNA is attacked and a library is constructed using Tn5 transposase. However, these methods have disadvantages such as low accuracy of traceability results, the need for deep sequencing, and high costs.
[0052] The present invention uses enzymes (such as transposases or endonucleases) to directly attack body fluids to fragment the free DNA therein and add connectors, thereby realizing direct library construction of body fluid free DNA; the method of the present invention not only has simple steps and low library construction costs, but also reduces information loss during sequencing, and retains the fragment information of body fluid free DNA to the maximum extent, especially retains the information of nucleosomal DNA. Therefore, the library construction method for body fluid free DNA provided by the present invention can not only realize the micro-library construction strategy of body fluid free DNA, but also obtain the apparent information of body fluid free DNA. By further analyzing and mining the obtained apparent information, especially the relevant information of nucleosomal DNA, tissue tracing can also be achieved.
[0053] The method provided by the present invention provides a new research method for the study of free DNA in body fluids, and has good application prospects in clinical applications such as prenatal diagnosis, early detection of tumors and new disease monitoring. BRIEF DESCRIPTION OF THE DRAWINGS
[0054] Figure 1 This is a data graph showing the number of plateau cycles determined by qPCR in Example 1;
[0055] Figure 2 It is the sample amplification curve diagram in Example 1;
[0056] Figure 3 This is a graph showing the results of the detection of some samples in Example 1 after magnetic bead double selection using Agilent 2100;
[0057] Figure 4 is the correlation between the data obtained by sequencing the samples in Example 1;
[0058] Figure 5 The enrichment diagram of the fragments obtained after sequencing in Example 1 in the transcription start region of the housekeeping gene and the silent gene respectively;
[0059] Figure 6 This is the clustering result of the sample sequencing data and tissue sequencing data in Example 1. DETAILED DESCRIPTION
[0060] For the convenience of understanding the present invention, the present invention lists the following embodiments. It should be understood by those skilled in the art that the embodiments are only to help understand the present invention and should not be regarded as specific limitations of the present invention.
[0061] Example 1 Library construction and epigenetic information analysis of peripheral blood free DNA
[0062] This example includes a series of steps including plasma sample preparation, direct Tn5 transposition into plasma, DNA amplification after transposition, Tn5 library construction, PE50+10 sequencing, nucleosome fragment screening, etc. Tn5 transposase was prepared according to the instructions of TruePrep Mini DNA Sample Prep Kit of Vazyme.
[0063] 1. Plasma sample preparation
[0064] 1.1 Plasma sample collection
[0065] Collect 10 mL of whole blood sample from a healthy person. Centrifuge at 1600 g for 10 min at 4°C. Take the supernatant (i.e. plasma) and transfer it to a new 15 mL centrifuge tube.
[0066] 1.2 Plasma purification (either of the following two methods can be used)
[0067] 1.2.1 Method 1:
[0068] Filter filtration method: Take 3 mL of plasma and filter it into a new EP tube using a 10 mL syringe and a 0.2 μm filter (about 0.5 mL loss).
[0069] 1.2.2 Method 2:
[0070] Secondary centrifugation method: After the plasma is centrifuged at 4°C, 16000g for 10 min, the supernatant is transferred to a new 15 mL centrifuge tube.
[0071] 2. Transposition reaction of part of plasma (i.e., the method of the present invention directly uses plasma for transposition reaction)
[0072] 2.1 Preparation of Adapter Mix
[0073] 2.1.1 Reference primer names and sequences:
[0074] Primer A: 5′-CTGTCTCTTATACACATCT-3′ (SEQ ID NO: 1)
[0075] Primer B: 5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3′ (SEQ ID NO: 2)
[0076] Primer C: 5′-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-3′ (SEQ ID NO: 3)
[0077] 2.1.2 Dissolve Primer A, Primer B, and Primer C to 100 μM using annealing buffer.
[0078] 2.1.3 Prepare the following reaction systems respectively, see Table 1:
[0079] Table 1 Preparation system of joint mixture
[0080]
[0081] 2.1.4 Vortex annealing product 1 and annealing product 2 to mix thoroughly, centrifuge briefly to return the solution to the bottom of the tube. Place in a PCR instrument and perform the following reaction program: 75℃ for 15min; 60℃ for 10min; 50℃ for 10min; 40℃ for 10min; 25℃ for 30min.
[0082] 2.1.5 After the reaction is completed, annealing product 1 and annealing product 2 are mixed in equal volumes and mixed evenly. The mixture is named as adapter mix and stored at -20°C.
[0083] 2.2 Encapsulation of the adapter mixture with Tn5 transposase to obtain a transposase-encapsulated complex
[0084] 2.2.1 Add the reaction components in the sterilized PCR tube in sequence, see Table 2; among them, Tagment Enzyme Advanced V5S BGI V5S reagent containing 1000U Tn5 transposase (supplier: BGI, product number: BGE005S).
[0085] Table 2 Adapter mixture and Tn5 transposase embedding system
[0086]
[0087] 2.2.2 Use a pipette to gently pipette and mix thoroughly.
[0088] 2.2.3 The reaction was carried out at 25°C for 60 min. The reaction product was named Tagment Enzyme AdvancedMix V5S and stored at -20°C.
[0089] 2.3 Blood free DNA fragmentation
[0090] Prepare the plasma transposition system (see Table 3). After preparation on ice, mix well and perform the transposition reaction on a constant temperature metal mixer at 37°C for 60 minutes.
[0091] Table 3 Plasma transposition reaction system
[0092]
[0093]
[0094] 3. Extraction of plasma free DNA after transposition
[0095] 3.1 Extraction was performed using the Magen blood free DNA extraction kit (MAGEN MD5432-01).
[0096] 3.2 After the transposition reaction is completed, add 25 μL of proteinase K and 35 μL of MagBind magnetic beads to a new 1.5 mL centrifuge tube.
[0097] 3.3 Transfer the sample to a centrifuge tube containing proteinase K. Vortex to mix for 5 seconds.
[0098] 3.4 Add 700 μL MLE to the sample, vortex to mix, and incubate at 55°C for 15 minutes.
[0099] 3.5 Transfer to the magnetic rack and let it stand for 5 to 10 minutes to absorb the magnetic beads.
[0100] 3.6 Carefully discard all the solution.
[0101] 3.7 Add 320 μL of buffer MW1 and vortex to mix for 15 seconds.
[0102] 3.8 Transfer to the magnetic rack and let it stand for 3 to 5 minutes to absorb the magnetic beads. Carefully aspirate and discard all the solution.
[0103] 3.9 Add 320 μL of buffer MW2 and vortex to mix for 15 seconds.
[0104] 3.10 Transfer to the magnetic rack and let it stand for 3 to 5 minutes to absorb the magnetic beads. Carefully aspirate and discard all the solution.
[0105] 3.11 Repeat steps 3.9-3.10.
[0106] 3.12 Briefly centrifuge to collect the droplets on the tube wall. Transfer to the magnetic rack and carefully discard all the solution.
[0107] 3.13 Air dry for 5-10 minutes.
[0108] 3.14 Add 20 μL of buffer AE and mix by pipetting.
[0109] 3.15 Let stand at room temperature for 3 minutes.
[0110] 3.16 Transfer to a magnetic rack, let stand for 3 minutes, and dissolve using the same method.
[0111] 3.17 Transfer the DNA solution to a new 1.5 mL centrifuge tube.
[0112] 3.18 Qubit assay concentration.
[0113] 4. Fragmented DNA Amplification
[0114] 4.1 Prepare the PCR reaction system in a 0.2 mL PCR tube according to Table 4.
[0115] Table 4 Transposition product first amplification reaction system
[0116]
[0117] *Note: The DNA solution is the purified DNA solution obtained in step 3.17 of Example 1; and the DNA solution used in the following Comparative Example 1 is the purified DNA solution obtained in step 1.4 of Example 1.
[0118] N5 Primer:
[0119] Pho-GAACGACATGGCTACGATCCGACTTTCGTCGGCAGCGTC (SEQ ID NO: 5);
[0120] N7 Primer:
[0121] TGTGAGCCAAGGAGTTGTTGTCTTCNNNNNNNNNNGTCTCGTGGGCTCGG (SEQ ID NO: 6),
[0122] Where NNNNNNNNNN is a label sequence composed of 10 random bases, and the label sequence used for each sample is different.
[0123] 4.2 Perform the first amplification according to the following parameters:
[0124]
[0125]
[0126] 5 Q-PCR identification and secondary amplification
[0127] 5.1 Prepare Q-PCR reaction system (as shown in Table 5):
[0128] Table 5 Fluorescence quantitative PCR identification reaction system with added cycle number
[0129]
[0130] 5.2 Perform qPCR according to the following parameters:
[0131]
[0132] like Figure 1In the qPCR linear amplification Rn / Cycle curve, the cycle number corresponding to 1 / 3 of the fluorescence intensity in the plateau phase is the number of cycles N that need to be added.
[0133] 5.3 Perform the second amplification according to the following parameters:
[0134]
[0135] Where N is the number of cycles determined in step 5.2. The sample amplification curve is shown in Figure 2 .
[0136] 6 XP magnetic beads double selection
[0137] 6.1 Check the volume in the PCR tube and add NF-H2O to 50 μL;
[0138] 6.2 Add 40 μL magnetic beads (0.8×), mix well by pipetting, and let stand at room temperature for 5 minutes;
[0139] 6.3 Place on the magnetic stand for 2 minutes and transfer the supernatant to a new tube (the DNA fragments in the supernatant are all less than 350 bp);
[0140] 6.4 Add 35 μL magnetic beads (0.7×), mix well, and let stand at room temperature for 5 minutes;
[0141] 6.5 Place on the magnetic rack for 2 minutes and remove the supernatant containing small DNA fragments and RNA;
[0142] 6.6 Keep it on the magnetic stand and add 150 μL pre-cooled 80% ethanol to wash twice (30 seconds);
[0143] 6.7 Keep it on the magnetic base for 5 minutes to allow the water to evaporate;
[0144] 6.8 To elute DNA, add 20 μL TE Buffer (AMBION AM9858), gently pipette to mix, and incubate at room temperature for 5 min;
[0145] 6.9 Place on the magnetic stand for 2 minutes and transfer the supernatant to a new tube without sucking up the magnetic beads;
[0146] 6.10 Qubit dsDNA High sensitivity assay (INVITROGEN Q32854) quantification
[0147] 6.11 The samples were tested by Agilent 2100. The test results are shown in Figure 3 .
[0148] 7. Library Circularization and Enzyme Digestion
[0149] The single-chain mediating fragment used in 7.1 is: 5′-GCCATGTCGTTCTGTGAGCCAAGG-3′ (SEQ ID NO: 4).
[0150] 7.2 Take 324.5 ng of the DNA solution purified in step 6, add 5 μL of single-stranded mediator fragment (20 μM), and make up to 70 μL with sterile ultrapure water.
[0151] 7.3 Transfer the mixture prepared in 7.2 to a thermal cycler, react at 95°C for 3 min, and immediately place on ice for 10 min.
[0152] 7.4 Prepare the single-stranded DNA ligation reaction system according to Table 6, mix well, and centrifuge quickly for 3 seconds.
[0153] Table 6 Single-stranded DNA ligation reaction system
[0154]
[0155] *Note: In Table 6, the DNA mixture is the solution obtained in step 7.3.
[0156] 7.5 Transfer to a thermal cycler, react at 37°C for 60 min, and store at 4°C.
[0157] 7.6 Prepare the enzyme digestion reaction system according to Table 7, mix well, and centrifuge quickly for 3 seconds.
[0158] Table 7 Single-stranded DNA restriction enzyme digestion reaction system
[0159]
[0160]
[0161] *Note: In Table 7, EXO I is exonuclease I and EXO III is exonuclease III.
[0162] 7.8 Transfer to a thermal cycler, react at 37°C for 30 min, and store at 4°C.
[0163] 8 Library Recovery
[0164] 8.1 Vortex and mix the PEG32 beads and pipette 170 μL into 128 μL PCR product. Use a pipette to gently pipette 10 times to mix thoroughly. Incubate at room temperature for 10 minutes.
[0165] 8.2 Briefly centrifuge the EP tube and place it on a magnetic stand to separate the magnetic beads and liquid. After the solution is clear (about 5 minutes), carefully remove the supernatant;
[0166] 8.3 Keep the EP tube in the magnetic rack and add 200 μL of freshly prepared 80% ethanol to rinse the magnetic beads. Incubate at room temperature for 30 seconds and carefully remove the supernatant;
[0167] 8.4 Repeat the above step, rinsing twice in total;
[0168] 8.5 Keep the EP tube in the magnetic rack and air dry it for 10 minutes with the cover open;
[0169] 8.6 Take the EP tube out of the magnetic rack and add 25 μL of sterile ultrapure water for elution. Use a pipette to gently blow and mix thoroughly, and leave at room temperature for 5 minutes. Centrifuge the reaction tube briefly and place it in a magnetic rack to separate the magnetic beads and liquid. After the solution is clear (about 5 minutes), carefully pipette the supernatant into a clean EP tube and store at -20°C;
[0170] 8.7 Take 1 μL of the purified product to measure the ssDNA concentration.
[0171] 9 Sequencing
[0172] According to the operating instructions of the BGI-SEQ500 sequencer, the constructed library was prepared into DNB (DNA nanoball), wherein 6 ng of the library was used and the RCA reaction was performed for 20 min. Then, the conventional PE50+10 strategy was used for sequencing on the sequencer.
[0173] It should be noted that the sequencing of the blood free DNA library obtained according to the present invention can be achieved by low-depth sequencing.
[0174] 10 Off-board data analysis
[0175] 10.1 Perform quality filtering and alignment on the Fastq sequencing data to obtain the Bam file after data alignment.
[0176] 10.2 By pairing the double-end fragments of the sequencing data, the full length and position information of each fragment is obtained.
[0177] 10.3 By filtering the fragment size, retaining large fragments (more than 60 bp), calculating the correlation between the samples where these fragments are located, and the enrichment of these fragments in the promoter and enhancer regions of different genes, the results are as follows: Figure 4 and 5 shown.
[0178] 10.4 Cluster analysis of these fragment data and DNase-seq data from different human tissues in the ENCODE database was performed. The results are as follows: Figure 6 shown.
[0179] Comparative Example 1
[0180] This comparative example adopts the method in the prior art, that is, directly extracting free DNA from blood and then performing a transposition reaction, as follows:
[0181] 1 Directly extract blood free DNA and then perform transposition reaction
[0182] 1.1 Extract blood-free DNA directly from the plasma purified in step 1.2 of Example 1 (for the specific method, refer to step 3 of Example 1).
[0183] 1.2 Prepare Tn5 transposition reaction system according to Table 8. After preparation on ice, mix well and transfer at 37℃ for 30min on a constant temperature metal mixer. Shake gently in between.
[0184] Table 8 Transposition reaction system after blood free DNA extraction
[0185]
[0186] 1.3 Terminate the reaction: Add 7.5 μL 5×NT buffer, pipette gently 20 times, and leave at room temperature for 5 minutes.
[0187] 1.4 1.8× magnetic beads to recover DNA samples
[0188] 1.4.1 Take out the XP magnetic beads (AGENCOURTA63882) from the 4°C refrigerator, mix well, and leave at room temperature for 10 min.
[0189] 1.4.2 Add 1.8×XP magnetic beads, pipette 10 times to mix, and let stand at room temperature for 5 min.
[0190] 1.4.3 Place it on the magnetic rack and let it stand for 2 minutes. The magnetic beads will be adsorbed and the liquid will become clear.
[0191] 1.4.4 Remove the supernatant, leaving 5 μL, and do not absorb the magnetic beads.
[0192] 1.4.5 Add 150 μL 80% ethanol, let stand for 30 seconds, and discard the supernatant.
[0193] 1.4.6. Repeat step 6.5, and finally absorb the ethanol and let it dry until the surface of the magnetic beads is no longer reflective.
[0194] 1.4.7 Remove the PCR tube from the magnetic stand, add 24 μL NF water to dissolve, pipette 10 times to mix,
[0195] Let stand at room temperature for 3 minutes.
[0196] 1.4.8 Place on the magnetic rack and let stand for 1 min until the liquid becomes clear.
[0197] 1.4.9 Transfer the supernatant to a new tube.
[0198] 1.4.10 Quantification using Qubit dsDNA High Sensitivity Detection Kit (INVITROGEN Q32854).
[0199] After obtaining the DNA sample solution according to step 1.4 of this comparative example 1, the experiment was continued according to steps 4-10 of Example 1 to analyze the enrichment of large fragments (more than 60 bp) in the promoter and enhancer regions of different genes in the library constructed according to the method of this comparative example 1. The results are as follows: Figure 4 shown.
[0200] like Figure 4 As shown, by comparing the results of Example 1 and Comparative Example 1, it can be found that it is obvious that the correlation between samples obtained according to the method of the present invention (Example 1) is higher than the correlation between samples obtained by the existing method (Comparative Example 1).
[0201] like Figure 5 As shown, the regional enrichment effect obtained by the method of the present invention (Example 1) is significantly enhanced compared with the enrichment effect of the existing method (Comparative Example 1).
[0202] like Figure 6 As shown, the sample data obtained by the method of the present invention and the data from different tissues of the human body are clustered together through a clustering method, indicating that the method of the present invention can capture the free DNA information of body fluids from different tissues of the human body and can further perform tissue tracing.
[0203] The applicant declares that the present application uses the above-mentioned embodiments to illustrate the detailed methods of the present application, but the present application is not limited to the above-mentioned detailed methods, that is, it does not mean that the present application must rely on the above-mentioned detailed methods to be implemented. The technicians in the relevant technical field should understand that any improvement to the present application, the equivalent replacement of the raw materials of the product of the present application, the addition of auxiliary components, the selection of specific methods, etc., all fall within the scope of protection and disclosure of the present application. SEQUENCE LISTING <110> Shenzhen BGI Life Sciences Institute <120> A method for constructing a library of free DNA in body fluids and its application <130> PIDC3200976PCN <160> 6 <170> PatentIn version 3.5 <210> 1 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> Primer A <400> 1 ctgtctctta tacacatct 19 <210> 2 <211> 33 <212> DNA <213> Artificial Sequence <220> <223> Primer B <400> 2 tcgtcggcag cgtcagatgt gtataagaga cag 33 <210> 3 <211> 34 <212> DNA <213> Artificial Sequence <220> <223> Primer C <400> 3 gtctcgtggg ctcggagatg tgtataagag acag 34 <210> 4 <211> twenty four <212> DNA <213> Artificial Sequence <220> <223> Mediator fragment <400> 4 gccatgtcgt tctgtgagcc aagg 24 <210> 5 <211> 39 <212> DNA <213> Artificial Sequence <220> <223> N5 Primer <400> 5 gaacgacatg gctacgatcc gactttcgtc ggcagcgtc 39 <210> 6 <211> 50 <212> DNA <213> Artificial Sequence <220> <223> N7 primer <220> <221> misc_feature <222> (26)..(35) <223> n is a, c, g, or t <400> 6 tgtgagccaa ggagttgttg tcttcnnnnn nnnnngtctc gtgggctcgg 50
Claims
1. A method for obtaining individual epigenetic information, comprising: (1) obtaining a cell-free DNA library from an individual's body fluids; (2) performing double-end sequencing and analysis on the body fluid free DNA library obtained in step (1) to obtain individual epigenetic information, wherein the analysis includes: filtering the fragment size, retaining the sequencing data of DNA fragments larger than 60 bp, so as to screen out nucleosomal DNA fragments, and obtaining the individual epigenetic information based on the sequencing data; Wherein, obtaining the individual's body fluid free DNA library in step (1) comprises: (a) Tn5 transposase is directly applied to a body fluid sample to fragment free DNA in the body fluid sample; (b) amplifying the fragmented DNA obtained in step (a) to obtain a body fluid free DNA library.
2. The method according to claim 1, wherein: Step (a) comprises: using a transposase to perform a transposition reaction on a body fluid sample containing free DNA, so as to fragment the free DNA and add a linker sequence to obtain DNA fragments containing the linker sequence.
3. The method according to claim 1, wherein: Step (a) also includes: after the free DNA is fragmented and a linker sequence is added, a nucleic acid extraction step is performed.
4. The method according to claim 2, wherein: The adapter used in the transposition reaction is an adapter mixture, which is prepared by the following steps: 1) Anneal primer A: 5'-CTGTCTCTTATACACATCT-3' and primer B: 5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3' to obtain annealing product 1; 2) Annealing primer A: 5'-CTGTCTCTTATACACATCT-3' and primer C: 5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAG-3' to obtain annealing product 2; 3) Mix the annealed product 1 and the annealed product 2 to obtain a joint mixture.
5. The method according to claim 4, wherein: The adapter mixture is embedded with the transposase to obtain a transposase-embedded complex for use in a transposition reaction.
6. The method according to claim 5, wherein: The adapter mixture was embedded with TagmentEnzyme Advanced V5S containing transposase.
7. The method according to claim 6, wherein: The volume ratio of the linker mixture to the Tagment Enzyme Advanced V5S is 1:20-1:
25.
8. The method according to claim 6, wherein: The volume ratio of the linker mixture to the Tagment Enzyme Advanced V5S is 1:24.
5.
9. The method according to claim 5, wherein: The embedding is performed at 22-28°C for 40-80 min.
10. The method according to claim 5, wherein: The embedding was carried out at 25°C for 60 min.
11. The method according to claim 5, wherein: The transposase-embedded complex is incubated with the body fluid sample under transposition reaction conditions to achieve a transposition reaction.
12. The method according to claim 11, wherein: For the transposition reaction, the volume ratio of the transposase-embedded complex to the body fluid sample is 1:50-1:
80.
13. The method according to claim 11, wherein: For the transposition reaction, the volume ratio of the transposase-embedded complex to the body fluid sample was 1:62.
5.
14. The method according to claim 11, wherein: The transposition reaction temperature is 35-40°C.
15. The method according to claim 11, wherein: The transposition reaction temperature was 37°C.
16. The method according to claim 11, wherein: The transposition reaction time is 55-65 min.
17. The method according to claim 11, wherein: The transposition reaction time is 60 min.
18. The method according to any one of claims 1 to 17, wherein: The amplification in step (b) includes two amplifications.
19. The method according to claim 18, wherein: After the first amplification, the number of additional cycles N required is determined by qPCR as the number of cycles for the second amplification.
20. The method according to any one of claims 1 to 17, further comprising: Step (c): Circularizing and digesting the body fluid free DNA library obtained in step b).
21. The method according to claim 20, wherein: The circularization includes denaturing the double-stranded DNA in the body fluid free DNA library into single-stranded DNA, and then connecting it through oligonucleotide fragments complementary to partial regions of the single-stranded DNA through base complementary pairing.
22. The method according to claim 21, wherein: A mediating fragment: 5'-GCCATGTCGTTCTGTGAGCCAAGG-3' was used to complementally pair with the single-stranded DNA to achieve circularization.
23. The method according to claim 20, wherein: The digestion is performed using Exonuclease I and Exonuclease III to remove non-circularized DNA.
24. The method according to claim 20, wherein: Step (c) also includes: a step of purifying the enzyme cleavage product; preferably, the purification is performed using magnetic beads.
